Delirium - PostoperativeNCT07776496
The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery.
A study testing Stellate Ganglion Block in people with Delirium - Postoperative and Inflammation Biomarkers, run by OMAR ABDELAZIZ ABOELFADL.
Trial summary
((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41). Study groups: Group S (Stellate Ganglion Block Group): Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction… Read more about this study
- Who is it for?
- Ages 65 to 85 years
- Conditions the study is for
- Delirium - Postoperative, Inflammation Biomarkers, Stellate Ganglion Block
- What is being tested?
- Stellate Ganglion Block
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 81 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2026to 1 Aug 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 85 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- All elderly (≥65 years) patients of both genders, as according to the World Health Organization, the chronologic age of 65 years was accepted by most developed countries in the world as a definition of "elderly" or older person. Patients scheduled for elective cardiac surgery under general anesthesia.14
- American Society of Anesthesiologists (ASA) physical status class II or III.
- Patients will be stratified according to their baseline surgical risk utilizing the EuroSCORE II tool >4%15.
- American Society of Anesthesiologists (ASA) physical status class II or III.
Who cannot join
- Pre-existing dementia or significant cognitive impairment.
- History of stroke or cerebrovascular disease.
- Contraindications to SGB (e.g., coagulopathy, local infection, or anatomical abnormalities).
- Preoperative use of antipsychotics or antidepressants.
- Sinus bradycardia <50bpm \&complete heart block
- BMI>35
Show all 9Show fewer
- Redo or emergency surgery.
- On preoperative mechanical ventilation and long sedation time.
- Low EF patients <35%.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery
((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41).
Study groups:
Read more
Group S (Stellate Ganglion Block Group):
Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.
Group C (Control Group):
Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.
Read the detailed description
((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41).
Study groups:
Group S (Stellate Ganglion Block Group):
Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.
Group C (Control Group):
Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.
Ultrasound guided left stellate ganglion block technique. Sedative dose of IV midazolam (1-2 mg) will be given to the patient in the preanesthetic room under supplemental oxygen nasal cannula 2-4L and electrocardiography (ECG) and pulse oximetry monitoring. Then, under local anesthesia 1% Lidocaine and complete aseptic conditions, arterial line will be inserted after ALLEN test for blood flow into the radial artery of either side for invasive blood pressure (IBP) monitoring and arterial blood gases (ABG) analysis. After that, the patient will be shifted to the operating room (OR) and Pulse oximetry, non-invasive blood pressure (NIBP), invasive blood pressure (IBP) and 5 lead electrocardiography (ECG) will be attached.
The patient will be positioned supine with the head tilted to the right and a thin cushion placed under the lt shoulder to better expose the neck. The skin will be disinfected, and patients will be instructed to avoid speaking, swallowing or making other movements during the procedure, raising their hands if they experience discomfort.
A trained anesthesiologist will use the SonoSite S series ultrasound machine (FUJIFILM SonoSite, Bothell, Washington, USA) to position the HFL38x/13-6 MHz high-frequency linear array probe horizontally at the C6 level. The internal jugular vein, common carotid artery and long neck muscle will be identified through transverse scanning. For patients in the SGB group, a 25-gauge needle will be inserted laterally at the level at C6, with the needle tip reaching the fascia plane of the sympathetic nerve chain, deep to the posterior fascia layer of the carotid sheath and superficial to the fascia covering the long neck muscle. After confirming negative pressure aspiration with no blood return, 5 mL of 0.25% bupivacaine will be injected into the SG. The anesthesiologist will assess the success of the SGB based on the presence of Horner's syndrome, characterized by miosis, ptosis, enophthalmos, nasal congestion, conjunctival congestion, facial redness, absence of sweating and a warm sensation. Control group patients will not receive any block even SHAM block.
General anesthesia technique and intraoperative management. Anesthesia will be induced with fentanyl (1-2 mcg /kg), Propofol (.5-1.5mg/kg) injected slowly and after ensuring adequate depth of anesthesia, rocuronium (0.9 mg/kg) will be given to facilitate endotracheal intubation with a cuffed appropriate size endotracheal tube and after ensuring the correct position and adequacy of ventilation are confirmed with capnography and lung auscultation, the tube is fixed, and the patient is ventilated (Datex-Ohmeda 7100 anesthesia machine) with 6 to 8 ml /kg predicted body weight using volume-controlled mode of ventilation. Respiratory rate is set initially to 12 breaths/ min and adjusted subsequently according to arterial blood gas (ABG) analysis to maintain normocarbia using. Central Venous Catheter, urinary catheter, and nasopharyngeal temperature probe will be inserted under completely aseptic technique. Anesthesia will be maintained with sevoflurane carried by oxygen/air mixture (the ratio is adjusted to maintain SpO2 between 94 % to 98 %), fentanyl (1:5 mic /kg/hr.) and rocuronium (0.3 mg/kg/h). Additional increments of fentanyl (2 mcg/kg) will be administered if mean arterial blood pressure (MAP) or heart rate (HR) rise in response to stressful surgical stimuli greater than 20% above baseline. The following parameters will be continuously monitored during the procedure: Heart rate and rhythm, O2 saturation by pulse oximetry (SpO2), end-tidal CO2, Invasive arterial blood pressure, central venous pressure using (CVP), Core body temperature using esophageal probe, urine output, and neuromuscular blockade using peripheral nerve stimulation.
Cardiopulmonary Bypass
- Standardized CPB protocol for all patients:
- Membrane oxygenator, arterial line filter.
- Priming: saline 1000-1500 mL with 5000 IU heparin.
- Anticoagulation: Heparin 300-400 IU/kg to maintain ACT >480 seconds.
- Flow rate: 2.2-2.4 L/min/m².
- Temperature: Moderate hypothermia (32-34°C) or normothermia (36-37°C) per surgeon preference (will be recorded and analyzed).
- Myocardial protection: Antegrade cold blood cardioplegia or Custodial® per institutional standard.
During CPB:
- Propofol infusion continued as needed for sedation.
- Neuromuscular blockade maintained.
- Being tested
- Stellate Ganglion Block
- Keywords
- postoperative Delirium, stellate ganglion block, SGB, IL6, Inflammatory biomarkers
- Medical subject headings
- Emergence Delirium
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stellate Ganglion BlockProcedure or surgery
ultrasound guided left stellate ganglion block in patients undergoing CABG surgery to compare with control group which not receive any block even SHAM block and show its effect on reducing inflammatory biomarkers especially il6 and its effect in reducing postoperative delirium
| Study group | Role | What they receive |
|---|---|---|
| stellate ganglion block | Experimental | Group S (Stellate Ganglion Block Group):
Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome. Receives: Procedure: Stellate Ganglion Block |
| control | No intervention | Group C (Control Group): Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interleukin 6 (IL-6) level in pg/ml change from baseline
Measured: 0 (baseline) and 6 hours after cardiopulmonary bypass
Secondary outcomes (9)
1. Incidence of postoperative delirium
A trained nurse will evaluate the patients two times (06:00-08:00 and 18:00-20:00). The confusion assessment method CAM-ICU. This method includes the following four evaluation indicators: (1) changes in mental state or fluctuations in consciousness levels during acute attacks; (2) lack of concentration; (3) confused thinking and (4) changes in level of consciousness. If both features 1 and 2 are positive and at least one of the features 3 or 4 is positive, the diagnosis is delirium. Subtypes of delirium are classified according to RASS score: hyperactive type (RASS >0), hypoactive type (RASS<0), and mixed type (alternating between hypoactive and hyperactive types).
Measured: day 0 to 3 days after successful extubation
2. Delirium severity will be assessed using the Delirium Rating Scale-Revised-98.
This scale features 16 items rated by clinicians and is divided into two sections: one with 13 severity items and another with three diagnostic items. Each severity item is scored from 0 to 3 points, while the diagnostic items are rated from 0 to 2 or 3 points.
Measured: day 0 to 3 days after successful extubation
3. CRP in mg/L, neutrophil to lymphocyte ratio (NLR) and Platelet to white cell ratio (PWR).
Measured: day 0 (baseline) to day 3
4. Creatinine baseline level in mg/dl, 24 h postoperatively, 48 h postoperatively, and the urine output was recorded on the first and second postoperative days.
Measured: 0 (baseline) to 48 hours postoperative
6. Total intraoperative opioid consumption
Measured: 0 hour From induction of anesthesia to 5 hours after induction of anesthesia
7. Postoperative opioid consumption (MME)
Measured: at 2, 6, 12, 24, and 48 hours post-extubation.
8. ICU length of stay
Measured: From icu admission to 10 days after icu admission
9. Hospital length of stay (day from surgery to hospital discharge).
Measured: From hospital admission to 10 days postoperative
10. Complications during and after the operation were monitored until the patient was discharged.
including pleural effusion, pericardial effusion, arrhythmia, organ failure, and surgical incision infections.
Measured: From 0 hour (inter-operative) to 72 hours (postoperative)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start1 Dec 2026 (estimated)
- Primary completion1 Mar 2028 (estimated)
- Study completion1 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Delirium - PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 81 participants (estimated)
Sponsor and investigators
- Lead sponsor
- OMAR ABDELAZIZ ABOELFADL
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, OMAR ABDELAZIZ ABOELFADL, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07776496
- Sponsor's protocol ID
- Lt SGB in CABG
- Status last verified
- Aug 2026
- First submitted
- 30 Jul 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No